ClinicalTrials.gg
CompletedNCT06374394Updated Dec 26, 2025Results posted

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine and COVID-19 mRNA vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 24 sites in 4 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
841
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
10th of 17
841 · median 976
Started
2024
with 6 others
Phase 3
15 of 17
none open now
Registered
10th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 10th largest by enrollment, is one of 7 that started in 2024, is one of 15 in phase 3, and was the 10th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

This study is assessing the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • RSV
  • Respiratory Syncytial Virus
  • COVID-19 mRNA vaccine
  • Immunogenicity
  • Safety
  • Reactogenicity
  • Older Adults
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits).

Note: In case of physical incapacity that would preclude the self-completion of the diary cards, either site staff can assist the participant (for activities performed during site visits) or the participant may assign a caregiver to assist him/her with this activity (for activities performed at home). However, at no time will the site staff or caregiver evaluate the participant's health status while answering diaries or make decisions on behalf of the participant.

  • Written or witnessed obtained from the participant (participant must be able to understand the informed consent) prior to performance of any study-specific procedure.
  • A male/female of ≥50 Years of age (YOA) at the time of the first study intervention administration.
  • Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.

  • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living.

Participants who have received previously a SARS-CoV-2 vaccine, being administered at least 3 months prior to study vaccination.

  • Female participants of non- may be enrolled in the study. Non childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and .
  • Female participants of childbearing potential may be enrolled in the study if the participant.

    • has practiced adequate from 1 month prior to study intervention administration and agreed to continue adequate contraception for at least 1 month after the last vaccination.
    • has a negative pregnancy test on the day of and prior to study intervention administration.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • History of any reaction or likely to be exacerbated by any component of the study interventions, including a known history of severe allergic reaction (e.g., anaphylaxis).
  • Any confirmed or suspected or immunodeficient condition, resulting from disease (e.g., current , ) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat disorders), based on medical history and physical examination (no laboratory testing required).
  • Any history of myocarditis or pericarditis.
  • Recurrent history or uncontrolled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g. completion of diary cards, attend regular phone calls/study site visits).
  • Serious or unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival up to study end).
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any SAE attributed to a previous dose of the SARS-CoV-2 mRNA vaccine.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
  • Recent SARS-CoV-2 infection within 3 months prior to the COVID-19 vaccine dose administration. Timelines to be determined from symptoms onset or positive COVID-19 test (if infection was asymptomatic).

Prior/Concomitant Therapy Use of any or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the first dose of study interventions and ending 30 days after the last vaccine administration, or their planned use during the study period.

  • Planned administration of a vaccine in the period starting 30 days before the first dose and ending 30 days after the last dose of study intervention(s) administration*, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after the study vaccination.

    *If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine, provided it is used according to the local governmental recommendations and Sponsor is notified.

  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the last blood sampling visit.

    • Up to 3 months prior to the study intervention administration:

      • For , this will mean prednisone equivalent ≥ 20 mg/day. Inhaled and topical steroids are allowed.
      • Administration of immunoglobulins and/or any blood products or plasma derivatives.
    • Up to 6 months prior to study intervention administration: long-acting immune modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies and antitumoral medication.
  • Administration of any SARS-CoV-2 vaccine during the 3 months preceding the study COVID-19 mRNA vaccine administration.
  • Previous vaccination with licensed or investigational RSV vaccine. Prior/Concurrent Clinical Study Experience
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device).

Other Exclusion Criteria

  • Pregnant or lactating female participant.
  • Female participant planning to become pregnant or planning to discontinue precautions.
  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Participation of any study personnel or their immediate dependents, family, or household members.
  • Planned move during the study conduct that prohibits participation until study end.
  • Bedridden participants.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
841 participants (actual)

Study arms

  • Experimental
    Co-Ad Group

    Participants received a single dose of RSVPreF3 OA vaccine and a single dose of COVID-19 mRNA vaccine at Day 1, in different arms.

    Biological: RSVPreF3 OA investigational vaccine · Biological: COVID-19 mRNA vaccine

  • Active comparator
    Control Group

    Participants received a single dose of COVID-19 mRNA vaccine at Day 1, followed by a single dose of RSVPreF3 OA vaccine at Day 31.

    Biological: RSVPreF3 OA investigational vaccine · Biological: COVID-19 mRNA vaccine

Interventions

  • 1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1 to participants in the Co-ad Group and on Day 31 to participants in the Control Group.

  • 1 dose of COVID-19 mRNA vaccine is administered intramuscularly on Day 1 to participants in the Co-ad and Control Groups.

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

    RSV-A neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)

  2. Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

    RSV-B neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)

  3. Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA Vaccination

    SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were provided as group GMTs and expressed as titers. The neutralizing titer was calculated as the reciprocal serum dilution corresponding to the 50% signal reduction (NT50). Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.

    Time frame: At 1 month post-COVID-19 mRNA vaccine dose administration (at Day 31 for both groups)

Secondary outcomes

  1. RSV-A Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination

    Neutralizing titers for RSV-A were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)

  2. Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination

    The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)

  3. RSV-A Neutralizing Titers Expressed as Seroresponse Rate (SRR) at 1 Month After RSVPreF3 OA Vaccination

    The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to (\>=) 4.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)

  4. Percentage of Participants Having RSV-A Neutralizing Titers Greater or Equal to the Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination

    Percentage of participants with RSV-A neutralizing titers \>= to the assay cut-off value (i.e. lower limit of quantification \[LLOQ\]) are presented.

    Time frame: At pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group) and at 1 month post-RSVPreF3 OA vaccine dose administration (Day 31 for Co-Ad Group and Day 61 for Control Group)

  5. RSV-B Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination

    Neutralizing titers for RSV-B were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)

  6. MGI of RSV-B Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination

    The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)

  7. RSV-B Neutralizing Titers Expressed as SRR at 1 Month After RSVPreF3 OA Vaccination

    The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) \>= 4.

    Time frame: At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)

  8. Percentage of Participants Having RSV-B Neutralizing Titers Greater or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination

    Percentage of participants with RSV-B neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.

    Time frame: At pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group) and at 1 month post-RSVPreF3 OA vaccine dose administration (Day 31 for Co-Ad Group and Day 61 for Control Group)

  9. SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Expressed as GMT at 1 Month After COVID-19 mRNA Vaccination

    The SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

    Time frame: At 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups)

  10. MGI of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After COVID-19 mRNA Vaccination

    The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.

    Time frame: At 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups) compared to pre-vaccination (at Day 1 for both groups)

  11. Percentage of Participants Having SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Greater Than or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After COVID-19 mRNA Vaccination

    Percentage of participants with SARS-CoV-2 Omicron XBB.1.5 neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.

    Time frame: At pre-vaccination (Day 1 for both groups) and at 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups)

  12. Number of Participants Reporting Each Solicited Administration Site Event, for Each Type of Vaccine Administered

    The solicited administration site events after vaccination included pain, erythema/redness, and swelling. Any = occurrence of the events regardless of the intensity grade.

    Time frame: Within 4 days (the day of administration and 3 subsequent days) after each type of vaccine (RSVPreF3 OA vaccine administered at Day 1 for Co-Ad Group and at Day 31 for Control Group, COVID-19 mRNA vaccine administered at Day 1 for both groups)

  13. Number of Participants Reporting Each Solicited Systemic Event, for Each Day of Dose Administered

    The solicited systemic events after vaccination included arthralgia, fatigue, fever (pyrexia), headache and myalgia. Fever was defined as body temperature equal or greater than 38 degrees Celsius (°C). Any = occurrence of the events regardless of the intensity grade.

    Time frame: Within 4 days (the day of dose administered and 3 subsequent days) after each dose (administered at Day 1 for Co-Ad Group and at Days 1 and 31 for Control Group)

  14. Number of Participants Reporting Unsolicited Adverse Events (AEs), for Each Day of Dose Administered

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs must had been communicated by participant/participant's caregiver(s) who had signed the informed consent. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.

    Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after each dose (dose administered at Day 1 for Co-Ad Group and at Days 1 and 31 for Control Group)

  15. Number of Participants Reporting Any Serious Adverse Events (SAEs)

    An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.

    Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-Ad Group and Day 31 for Control Group])

  16. Number of Participants Reporting Any Potential Immune-mediated Diseases (pIMDs)

    The pIMD was defined as a subset of adverse events of special interest that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.

    Time frame: Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-Ad Group and Day 31 for Control Group])

07

Results

Posted Dec 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneCo-Ad GroupControl Group
Started417416
Completed409398
Not completed818
Withdrew: Adverse event02
Withdrew: Lost to follow-up69
Withdrew: Withdrawal by subject17
Withdrew: Other10

Outcome measures

PrimaryAdjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

RSV-A neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Reported as:
Geometric mean · Titers
Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
TitersCo-Ad GroupControl Group
Adjusted Geometric Mean Titers (GMT) of Respiratory Syncytial Virus-A (RSV-A) Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination7885.8 (7168.1 to 8675.3)8803.4 (7985.0 to 9705.7)
Statistical analysis
  • Co-Ad Group vs Control Group · ANCOVA · Geometric mean ratio (gmr): 1.12 · 95% CI 0.97 to 1.28The GMR is based on the back transformation of the group comparisons in the ANCOVA model applied to the logarithmically-transformed titers.
PrimaryAdjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination

RSV-B neutralizing titers were provided as group GMTs and expressed as estimated dilution 60 (ED60) titers. Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Reported as:
Geometric mean · Titers
Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination
TitersCo-Ad GroupControl Group
Adjusted GMTs of RSV-B Neutralizing Titers at 1 Month After the RSVPreF3 OA Vaccination7333.3 (6678.6 to 8052.0)7903.1 (7182.6 to 8695.9)
Statistical analysis
  • Co-Ad Group vs Control Group · ANCOVA · Gmr: 1.08 · 95% CI 0.94 to 1.23The GMR is based on the back transformation of the group comparisons in the ANCOVA model applied to the logarithmically-transformed titers.
PrimaryAdjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA Vaccination

SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were provided as group GMTs and expressed as titers. The neutralizing titer was calculated as the reciprocal serum dilution corresponding to the 50% signal reduction (NT50). Adjusted GMTs are derived using an ANCOVA model on log10-transformed titers for the neutralization assay. The final ANCOVA model adjusted for baseline differences (in the pre-dose titers) includes treatment group and age category (age at vaccination: 50-59, 60-69 or ≥70 years) as fixed effects, and the pre-dose log10-transformed titers as a covariate.

Time frame:
At 1 month post-COVID-19 mRNA vaccine dose administration (at Day 31 for both groups)
Reported as:
Geometric mean · Titers
Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA Vaccination
TitersCo-Ad GroupControl Group
Adjusted GMTs of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After the COVID-19 mRNA Vaccination1063.6 (960.2 to 1178.2)1392.0 (1256.9 to 1541.5)
Statistical analysis
  • Co-Ad Group vs Control Group · ANCOVA · Gmr: 1.31 · 95% CI 1.13 to 1.51The GMR is based on the back transformation of the group comparisons in the ANCOVA model applied to the logarithmically-transformed titers.
SecondaryRSV-A Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination

Neutralizing titers for RSV-A were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Reported as:
Geometric mean · Titers
RSV-A Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination
TitersCo-Ad GroupControl Group
RSV-A Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination8119.1 (7316.6 to 9009.7)8407.1 (7611.6 to 9285.8)
SecondaryMean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination

The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
Reported as:
Geometric mean · Ratio
Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination
RatioCo-Ad GroupControl Group
Mean Geometric Increase (MGI) of RSV-A Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination8.31 (7.46 to 9.26)10.21 (9.20 to 11.33)
SecondaryRSV-A Neutralizing Titers Expressed as Seroresponse Rate (SRR) at 1 Month After RSVPreF3 OA Vaccination

The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to (\>=) 4.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
Reported as:
Number · Percentage of participants
RSV-A Neutralizing Titers Expressed as Seroresponse Rate (SRR) at 1 Month After RSVPreF3 OA Vaccination
Percentage of participantsCo-Ad GroupControl Group
RSV-A Neutralizing Titers Expressed as Seroresponse Rate (SRR) at 1 Month After RSVPreF3 OA Vaccination73.8 (69.1 to 78.2)81.3 (76.9 to 85.2)
SecondaryPercentage of Participants Having RSV-A Neutralizing Titers Greater or Equal to the Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination

Percentage of participants with RSV-A neutralizing titers \>= to the assay cut-off value (i.e. lower limit of quantification \[LLOQ\]) are presented.

Time frame:
At pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group) and at 1 month post-RSVPreF3 OA vaccine dose administration (Day 31 for Co-Ad Group and Day 61 for Control Group)
Reported as:
Number · Percentage of participants
Percentage of Participants Having RSV-A Neutralizing Titers Greater or Equal to the Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination
Percentage of participantsCo-Ad GroupControl Group
At pre-vaccination100 (99.1 to 100)100 (99.1 to 100)
1 month post RSVPreF3 administration100 (99.1 to 100)100 (99.0 to 100)
SecondaryRSV-B Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination

Neutralizing titers for RSV-B were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group)
Reported as:
Geometric mean · Titers
RSV-B Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination
TitersCo-Ad GroupControl Group
RSV-B Neutralizing Titers Expressed as GMT at 1 Month After RSVPreF3 OA Vaccination7537.1 (6791.4 to 8364.5)7588.9 (6896.0 to 8351.5)
SecondaryMGI of RSV-B Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination

The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
Reported as:
Geometric mean · Ratio
MGI of RSV-B Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination
RatioCo-Ad GroupControl Group
MGI of RSV-B Neutralizing Titers at 1 Month After RSVPreF3 OA Vaccination6.79 (6.08 to 7.59)8.19 (7.35 to 9.12)
SecondaryRSV-B Neutralizing Titers Expressed as SRR at 1 Month After RSVPreF3 OA Vaccination

The SRR was defined as the percentage of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) \>= 4.

Time frame:
At 1 month post-RSVPreF3 OA vaccine dose administration (at Day 31 for Co-Ad Group and Day 61 for Control Group) compared to pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group)
Reported as:
Number · Percentage of participants
RSV-B Neutralizing Titers Expressed as SRR at 1 Month After RSVPreF3 OA Vaccination
Percentage of participantsCo-Ad GroupControl Group
RSV-B Neutralizing Titers Expressed as SRR at 1 Month After RSVPreF3 OA Vaccination66.8 (61.8 to 71.5)75.5 (70.8 to 79.9)
SecondaryPercentage of Participants Having RSV-B Neutralizing Titers Greater or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination

Percentage of participants with RSV-B neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.

Time frame:
At pre-vaccination (Day 1 for Co-Ad Group and Day 31 for Control Group) and at 1 month post-RSVPreF3 OA vaccine dose administration (Day 31 for Co-Ad Group and Day 61 for Control Group)
Reported as:
Number · Percentage of participants
Percentage of Participants Having RSV-B Neutralizing Titers Greater or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After RSVPreF3 OA Vaccination
Percentage of participantsCo-Ad GroupControl Group
At pre-vaccination100 (99.1 to 100)100 (99.1 to 100)
1 month post RSVPreF3 administration100 (99.1 to 100)100 (99.0 to 100)
SecondarySARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Expressed as GMT at 1 Month After COVID-19 mRNA Vaccination

The SARS-CoV-2 Omicron XBB.1.5 neutralizing titers against the pseudovirus bearing S protein were measured with neutralizing assay and the results were expressed as GMT. GMT is a descriptive statistic calculated directly from the observed titer values at the 1-month post-vaccination timepoint for all participants in the analysis set, without any statistical modelling or adjustment for covariates.

Time frame:
At 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups)
Reported as:
Geometric mean · Titers
SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Expressed as GMT at 1 Month After COVID-19 mRNA Vaccination
TitersCo-Ad GroupControl Group
SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Expressed as GMT at 1 Month After COVID-19 mRNA Vaccination1030.4 (925.2 to 1147.6)1407.3 (1244.5 to 1591.4)
SecondaryMGI of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After COVID-19 mRNA Vaccination

The MGI was defined as the geometric mean of the within participant ratios of the post-vaccination titer over the pre-vaccination titer.

Time frame:
At 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups) compared to pre-vaccination (at Day 1 for both groups)
Reported as:
Geometric mean · Ratio
MGI of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After COVID-19 mRNA Vaccination
RatioCo-Ad GroupControl Group
MGI of SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers at 1 Month After COVID-19 mRNA Vaccination4.25 (3.73 to 4.85)5.46 (4.74 to 6.30)
SecondaryPercentage of Participants Having SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Greater Than or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After COVID-19 mRNA Vaccination

Percentage of participants with SARS-CoV-2 Omicron XBB.1.5 neutralizing titers \>= to the assay cut-off value (i.e. LLOQ) are presented.

Time frame:
At pre-vaccination (Day 1 for both groups) and at 1 month post-COVID-19 mRNA vaccine dose administration (Day 31 for both groups)
Reported as:
Number · Percentage of participants
Percentage of Participants Having SARS-CoV-2 Omicron XBB.1.5 Neutralizing Titers Greater Than or Equal to Assay Cut-off Value at Pre-vaccination and at 1 Month After COVID-19 mRNA Vaccination
Percentage of participantsCo-Ad GroupControl Group
At pre-dose administration95.1 (92.5 to 97.0)94.3 (91.6 to 96.4)
1 month after COVID-19 mRNA vaccination99.7 (98.6 to 100)99.7 (98.6 to 100)
SecondaryNumber of Participants Reporting Each Solicited Administration Site Event, for Each Type of Vaccine Administered

The solicited administration site events after vaccination included pain, erythema/redness, and swelling. Any = occurrence of the events regardless of the intensity grade.

Time frame:
Within 4 days (the day of administration and 3 subsequent days) after each type of vaccine (RSVPreF3 OA vaccine administered at Day 1 for Co-Ad Group and at Day 31 for Control Group, COVID-19 mRNA vaccine administered at Day 1 for both groups)
Reported as:
Count of participants · Participants
Number of Participants Reporting Each Solicited Administration Site Event, for Each Type of Vaccine Administered
ParticipantsCo-Ad GroupControl Group
Erythema, within 4 days from COVID-19 mRNA Dosing1920
Erythema, within 4 days from RSVPreF3 OA Dosing3426
Pain, within 4 days from COVID-19 mRNA Dosing297264
Pain, within 4 days from RSVPreF3 OA Dosing302235
Swelling, within 4 days from COVID-19 mRNA Dosing1013
Swelling, within 4 days from RSVPreF3 OA Dosing209
SecondaryNumber of Participants Reporting Each Solicited Systemic Event, for Each Day of Dose Administered

The solicited systemic events after vaccination included arthralgia, fatigue, fever (pyrexia), headache and myalgia. Fever was defined as body temperature equal or greater than 38 degrees Celsius (°C). Any = occurrence of the events regardless of the intensity grade.

Time frame:
Within 4 days (the day of dose administered and 3 subsequent days) after each dose (administered at Day 1 for Co-Ad Group and at Days 1 and 31 for Control Group)
Reported as:
Count of participants · Participants
Number of Participants Reporting Each Solicited Systemic Event, for Each Day of Dose Administered
ParticipantsCo-Ad GroupControl Group
Arthralgia, within 4 days from dosing at Day 18147
Arthralgia, within 4 days from dosing at Day 31—36
Fatigue, within 4 days from dosing at Day 1166115
Fatigue, within 4 days from dosing at Day 31—95
Fever, within 4 days from dosing at Day 1267
Fever, within 4 days from dosing at Day 31—9
Headache, within 4 days from dosing at Day 112098
Headache, within 4 days from dosing at Day 31—83
Myalgia, within 4 days from dosing at Day 1170117
Myalgia, within 4 days from dosing at Day 31—91
SecondaryNumber of Participants Reporting Unsolicited Adverse Events (AEs), for Each Day of Dose Administered

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study vaccine, which does not necessarily have a causal relationship with study vaccine. An unsolicited AE was an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs must had been communicated by participant/participant's caregiver(s) who had signed the informed consent. Unsolicited AEs included both serious and non-serious AEs. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.

Time frame:
Within 30 days (the day of vaccination and 29 subsequent days) after each dose (dose administered at Day 1 for Co-Ad Group and at Days 1 and 31 for Control Group)
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited Adverse Events (AEs), for Each Day of Dose Administered
ParticipantsCo-Ad GroupControl Group
Within 30 days after dosing at at Day 18771
Within 30 days after dosing at at Day 31—57
SecondaryNumber of Participants Reporting Any Serious Adverse Events (SAEs)

An SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.

Time frame:
Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-Ad Group and Day 31 for Control Group])
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Serious Adverse Events (SAEs)
ParticipantsCo-Ad GroupControl Group
Number of Participants Reporting Any Serious Adverse Events (SAEs)1614
SecondaryNumber of Participants Reporting Any Potential Immune-mediated Diseases (pIMDs)

The pIMD was defined as a subset of adverse events of special interest that included autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any = occurrence of the events regardless of the intensity grade or relation to study dose administration.

Time frame:
Throughout the study period (from Day 1 up to 6 months after the last dose administration [last dose given at Day 1 for Co-Ad Group and Day 31 for Control Group])
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Potential Immune-mediated Diseases (pIMDs)
ParticipantsCo-Ad GroupControl Group
Number of Participants Reporting Any Potential Immune-mediated Diseases (pIMDs)01

Adverse events

Collected over Solicited AEs were collected within 4 days post each vaccination. Unsolicited AEs were collected within 30 days post each vaccination. All cause mortality, SAEs and pIMDs were collected throughout the study period (from Day 1 up to 6 months post-last administration [last dose given at Day 1 for Co-ad Group and Day 31 for Control Group]).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Co-Ad Group0/417 (0%)16/417 (3.8%)365/417 (87.5%)
Control Group0/416 (0%)14/416 (3.4%)337/416 (81%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventCo-Ad GroupControl Group
Atrial flutterCardiac disorders0/4172/416
Cardiac failureCardiac disorders2/4170/416
Atrial fibrillationCardiac disorders1/4171/416
Angina pectorisCardiac disorders0/4171/416
BradycardiaCardiac disorders0/4171/416
Cardiac arrestCardiac disorders0/4171/416
Cardiac failure congestiveCardiac disorders0/4171/416
PericarditisCardiac disorders0/4171/416
PneumoniaInfections and infestations1/4171/416
Device related infectionInfections and infestations0/4171/416
Most frequent other events
Showing 10 of 140
Most frequent other events
EventCo-Ad GroupControl Group
Administration site painGeneral disorders336/417303/416
MyalgiaMusculoskeletal and connective tissue disorders170/417158/416
FatigueGeneral disorders166/417154/416
HeadacheNervous system disorders122/417137/416
ArthralgiaMusculoskeletal and connective tissue disorders84/41773/416
Administration site erythemaGeneral disorders41/41736/416
PyrexiaGeneral disorders26/41716/416
Administration site swellingGeneral disorders25/41719/416
DiarrhoeaGastrointestinal disorders4/41710/416
NauseaGastrointestinal disorders6/4177/416

Baseline characteristics

Exposed set included all participants that received at least one study administration dose.

Age, Continuous
Age, Continuous(YEARS)Co-Ad GroupControl GroupTotal
Mean63.7 ± 8.463.5 ± 8.463.6 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Co-Ad GroupControl GroupTotal
Female216223439
Male201193394
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Co-Ad GroupControl GroupTotal
Other Races5712
White378375753
Black or African American313263
Multiple112
Not reported213
08

Study locations

24 sites
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    North Charleston, South Carolina 29405, United States
  • GSK Investigational Site
    Newport News, Virginia 23606, United States
  • GSK Investigational Site
    Antwerp, 2000, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Kluisbergen, 9690, Belgium
  • GSK Investigational Site
    Mechelen, 2800, Belgium
  • GSK Investigational Site
    Breda, 4818 CK, Netherlands
  • GSK Investigational Site
    Enschede, 7512 KZ, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 BA, Netherlands
  • GSK Investigational Site
    Zutphen, 7207 AE, Netherlands
  • GSK Investigational Site
    A Coruña, 15006, Spain
  • GSK Investigational Site
    Barcelona, 08023, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Boadilla Del Monte Madrid, 28660, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28222, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Nov 2024, 6 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 18, 2024
StartActual
Apr 29, 2024
Primary completionActual
Nov 1, 2024
CompletionActual
Mar 31, 2025
Results first posted
Dec 26, 2025
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06374394
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Apr 29, 2024
Primary completion
Nov 1, 2024
Completion
Mar 31, 2025
Results posted
Dec 26, 2025
Last update
Dec 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arexvy · mRNA COVID-19 Vaccine

Start the discussion